

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.

- AASM Visual scoring system, 20-21, 22t-23t
- Abuse, with hypnotic medications, 221-225, 222-223
 - relative abuse liability, 221-224, 222-223
- Accidents
 - increase in, with insomnia, 74-77, 76
 - motor vehicle accidents, 74, 76
- ACE inhibitors, 158
- Acetylcholine (ACh), 30, 31t, 34
- Acquired immunodeficiency syndrome (AIDS)
- Actigraphy, 133
- Acute insomnia, 41, 41t, 47t
- Addiction, with hypnotic agents, 221-224, 222-223
- Adenosine, 33
- ADHD. *See Attention-deficit hyperactivity disorder.*
- Adjustment insomnia, 47t
- Adolescents, insomnia in, 54
- Adrenocorticotrophic hormone (ACTH), increased levels and insomnia, 61
- Advanced sleep-phase disorder, 111, 129t
- Age. *See also Elderly patients.*
 - effect on sleep stages, 21, 27
 - increased risk for insomnia with, 53t, 54, 55
 - sleep efficiency and, 55, 86
 - sleep fragmentation and, 21, 27, 54, 55
 - sleep needs and, 21
- Albuterol, 156
- Alcohol abuse
 - and abuse of hypnotic medications, 224
 - insomnia and, 99-100
 - as risk factor for insomnia, 53t
- Alcohol use
 - consumption with hypnotics cautioned against, 220
 - effect on sleep, 131
 - in evening, interference with sleep, 69t, 125t
 - as risk factor for insomnia, 53t
- Aldosterone receptor blockers, 158
- Allostatic signaling, 36
- Alzheimer's disease, 100
 - in association with insomnia, 100
 - caregivers, insomnia in, 100
 - as risk factor for insomnia, 53t
- Ambien (zolpidem). *See Zolpidem.*
- Ambien CR (zolpidem ER). *See Zolpidem ER.*
- American Academy of Sleep Medicine (AASM), 43
 - visual scoring system, 20-21, 22t-23t

- Amitriptyline, 149, 150t, 154
- Amphetamines, interference with sleep by, 101t, 131
- Angiotensin-converting receptor blockers (ARBs), 158
- Anticholinergic agents, 156
- Anticonvulsants, for insomnia, 184t, 227
- Antidepressants. See also *specific agents*.
 classes of, 149
 SSRIs, 149, 150t
 tricyclics (TCAs), 149, 150t, 203
 continuation of insomnia despite treatment, 148
 effects on sleep variables, 145-155, 150t-151t
 polysomnographic sleep patterns, 149-152
 hypnotic agents in combination with, 154-155, 154
 interference with sleep by, 130
 monotherapy, 149
 polytherapy, 149, 154-155, 154, 155
 receptor profiles of, 146-147, 148t
 sedating, in treatment of insomnia, 184t, 225-227
 sedating effects of, 148, 149, 150t-151t, 152
 use for insomnia, 184t, 225-227
 advantages of, 225
 dosage, 226
 doxepin, 202t, 203-205, 226
 escitalopram, 145-146, 146, 147
 eszopiclone, 145-146, 146, 147
 mirtazapine, 149, 151t, 226-227
 polytherapy for, 149, 154-155, 154, 155
 trazodone, 226
 worsening of insomnia with, 152
- Antiepileptic drugs
 use for insomnia, 184t, 227
 use for RLS, 156
- Antihistamines, 148t, 175, 176t
- Antipsychotics, 184t, 227
 adverse effects, 227
 effects on sleep latency and continuity, 145t
- Anxiety
 anticipatory anxiety, prior to bedtime, 96, 125
 anxiolytic effect of benzodiazepines, 188
 Hamilton Anxiety Scale, 146, 154, 155
 as risk factor for insomnia, 53t
 risk of developing, insomnia and, 82, 84
 triad of insomnia, depression, and anxiety, 97
- Anxiety disorders, 95-96, 143-146
 comorbid with insomnia, 82, 92-93, 92t, 95-96
 generalized anxiety disorder (GAD), 95
 treatment of, 143-146, 145t, 146, 147
 insomnia with, 92t, 95-96
 bidirectional relationship of, 93
- Anxiety disorders (*continued*)
 posttraumatic stress disorder (PTSD), 95
 treatment of, 145
 symptoms of, 92t
 treatment of, 143-146, 145t, 146, 147
- Apnea. See *Sleep apnea*.
- ARBs, 158
- Arousal neurophysiology, 29, 30, 31t, 59-63. See also *Hyperarousal*.
- Arousal system/centers, 29, 30-33, 31t
 factors modulating, 33-36, 35t
 flip-flop switch for, 33, 34
- Arousals during insomnia, 39, 40. See also *Awakening*.
 polysomnographic depiction of, 40
- Arthritis
 comorbid with insomnia, 91
 as risk factor for insomnia, 53t
- As-needed (PRN) use of insomnia medications, 217-219
- ASSM Visual scoring system, 20-21, 22t-23t
- Asthma, comorbid with insomnia, 91
- Attention-deficit hyperactivity disorder (ADHD), with insomnia, 99
- Automobiles
 accidents, 74, 76
 sleep driving, 220
- Awakening
 brief, 40, 40
 impact of, on sense of restfulness, 39, 40
 early, 39, 40, 43
 effects of antipsychotic agents on, 145t
 middle-of-the-night (MOTN), 124t, 183, 195-196
 PRN (as-needed) use of medication and, 217-219
 multiple, 39
- Barbiturates, 186
- Bedtime
 anticipatory anxiety prior to, 96
 excessive cognitive monitoring at, 68
 habits, 125
 inquiry about, in patient evaluation, 124, 124t
 lack of regular presleep ritual, 69t
 maladaptive behavioral practices around, 68-69, 69t, 125t
- Behavioral constructs in insomnia, 66-69, 67
 maladaptive behavioral practices, 68-69, 69t, 124, 125t
 sleep-related behaviors, 124-125, 124t, 125t
- Behavioral strategies for insomnia treatment, 163-174
 advantages of, 171
 cognitive and behavioral therapies, 163-170, 164t
 goals of, 166t-167t
 combining with pharmaceutical therapies, 168-170, 170
 delivery and implementation of, 172
 efficacy of, 163, 168-170, 170, 172

Behavioral strategies for insomnia treatment (*continued*)

- finding therapists for, 171, 172
 - implementation of, 172
 - insurance coverage and, 163
 - limitations of, 172
 - methods, 163-168, 164t, 166t-167t
 - brief behavioral treatment of insomnia (BBTI), 172
 - cognitive behavioral therapy for insomnia (CBT-I), 168-171, 169, 170, 172
 - cognitive therapy, 164t, 165, 167t
 - paradoxical intention, 164t, 167t, 168
 - relaxation therapy, 164t, 165-168, 167t
 - sleep hygiene education, 163-165, 164t, 166t
 - sleep restriction therapy, 164t, 165, 167t
 - stimulus control therapy, 164t, 165, 166t
 - variations in methodology, 172
 - primary care setting for, 163, 172
 - target pathways for, 168, 169, 170-171
 - in treatment algorithm, 144
- Beliefs about sleep, 68, 125
- Belsomra (suvorexant). See *Suvorexant*.
- Benzodiazepine receptor(s), 187-188, 187
- Benzodiazepine receptor agonists (BzRAs), 184t, 186-199.
- See also *specific agents*.
- abuse liability, 198, 221-224, 222-223
 - action mechanisms, 187-188
 - adverse effects of, 198
 - agents used for insomnia, 189t-191t
 - benzodiazepines, 188, 189t
 - nonbenzodiazepines, 188, 190t-191t
 - benzodiazepines, 188, 189t
 - in treatment of RLS, 156
 - cautions and contraindications, 198-199, 219-221, 220t
 - addiction and dependency, 198, 222-223
 - complex sleep-related behaviors, 220
 - pregnancy, 198-199, 219
 - clinical considerations for, 211-225
 - dosage, 190t-191t, 220-221
 - guidelines for use, 226t
 - long-term use, 211-217
 - half-life and, 211
 - intermittent long-term use, 211-212, 213
 - rebound insomnia, 211
 - tolerance, 211
 - withdrawal effects, 211
 - PRN and middle-of-the-night use, 217-219
 - safety, 219-221, 220t
 - vulnerable populations, 219-221, 220t
 - daytime carryover effects, 188, 219

Benzodiazepine receptor agonists (BzRAs) (*continued*)

- dosage, recommended, 189t-191t, 220-221
 - lowering of doses by FDA, 220-221
- efficacy, 188, 198t
 - effect on sleep variables, 197-198, 198t
 - in increasing total sleep time, 188, 197
 - in reducing sleep latency, 188, 194, 198t
 - in reducing WASO, 188, 197, 198t
- FDA-approved, 184t, 186-199
- GABA receptor binding of, 186-187, 187
- half-lives, 188, 189t-191t, 211
- indications and usage, 189t-191t
- nonbenzodiazepines, 188, 190t-191t
 - onset of action, 189t-191t
 - pharmacokinetic properties, 189t-191t
 - plasma concentrations, 188, 192, 193
 - as schedule IV, controlled agents, 198
 - selective (sBzRAs), 188, 190t-191t
- Beta-amyloid, 19
- β -Blockers, 158
- Beta/gamma activity, 61
- Biofeedback, in insomnia, 168
- Bipolar disorder
 - with comorbid insomnia, 98
 - screening for, 132
- Blindness, 106-107
 - circadian rhythm in, 107
 - sleep disorders and, 106-107, 112
- Blood pressure, high. See *Hypertension*.
- Brain activity
 - during sleep, 19-21, 24-26, 36
 - increased, in insomnia, 61-63, 62
- Brainstem mechanisms, 28-33, 29
- Breathing disorders. See *Sleep-related breathing disorders*.
- Brief behavioral treatment of insomnia (BBTI), 172
- Bright-light
 - prior to bedtime or during awakenings, 125t
 - therapy, for circadian rhythm disorders, 111, 112
- Bromide, in early therapy for insomnia, 184
- Bupropion
 - effects on sleep variables, 149, 151t
 - negative effects on sleep, 149
- Burdens associated with insomnia. See *Impairments and burdens*.
- BzRAs. See *Benzodiazepine receptor agonists*.
- Caffeine
 - effect on sleep, 65, 69t, 131
 - increased sensitivity to, 65
 - prior to bedtime, 125t
 - as risk factor for insomnia, 53t

- Calcium, 176t
- California poppy, 176t, 180-181
- Cancer, prevalence of insomnia with, 94
- Cardiovascular disease
 - comorbid with insomnia, 79-82, 92t, 112-113
 - treatment of, 158
 - congestive heart failure, 158
 - hyperarousal and, 92t, 113
 - hypertension, 80, 81, 113
 - incidence of, with insomnia, 79-82, 81
 - myocardial infarction (MI), 80, 113
 - risk for, 79-82, 81, 112, 113
 - stroke, 102
- Central nervous system depression, by sedative-hypnotic agents, 186, 219
- Cerebral cortex, 31t
- Chamomile, 176, 176t, 180
- Chest examination, 132
- CHF. See *Congestive heart failure*.
- Chloral hydrate, 184-186
- Cholinergic (ACh) neurons, 30, 31t, 34
 - anticholinergic medications, 156
- Chronic insomnia, 41, 41t, 46t
 - prevalence in primary care, 51
- Chronic obstructive pulmonary disease (COPD), 91, 108-109
 - associated with insomnia, 108-109
 - comorbid with insomnia, 91
 - treatment of, 156
 - effects of insomnia on, 156
 - hypoventilation in, 108
 - OSAS with, 109
 - ramelteon use in, 203
 - symptoms of, 128t
 - treatment of, 156
- Circadian rhythm disorders, 63-65, 107, 110-112
 - in association with insomnia, 63-65, 92t
 - diagnosis of, 110
 - genetic basis for, 65, 66
 - melatonin and, 63, 112, 157
 - naps and, 126
 - treatment of, 111, 112, 157, 178
 - types of, 110-112
 - advanced sleep-phase disorder, 111, 129t
 - blindness and, 107
 - delayed sleep-phase disorder, 110-111, 129t, 157, 178
 - free-running disorder, 112
 - non-24-hour sleep-wake disorder, 107, 112
 - shift-work disorder, 111-112, 178
 - time zone change syndrome (jet lag), 111
- Circadian rhythms, 33-36, 63-65, 199-201
 - blindness and, 107
 - free running, 107
 - in insomnia, 63-65
 - melatonin and, 64, 176-178, 199-201
 - morning light exposure and, 69t
 - neural systems controlling, 33-36, 35t, 199-201
 - practices that disrupt, 69t
 - sleep and, 63-65, 64
- Classification of insomnia, 40-45, 41t
 - diagnostic manuals, 42-45, 44t-45t, 46t-48t
 - by duration, 41, 41t, 43
 - undertreatment due to labeling as secondary, 42
- Clomipramine, 149, 150t
- Clozapine, 145t
- CNS depression by hypnotic agents, 186, 219
- Cocaine, interference with sleep by, 100, 101t, 131
- Cognitive and behavioral constructs in insomnia, 66-69, 67
 - catastrophizing, 68
 - exaggerated reactions, 68
 - excessive cognitive monitoring at bedtime, 68
- Cognitive and behavioral therapies, 79, 163-172
 - advantages of, 171
 - combining with pharmaceutical therapies, 168-170, 170
 - delivery and implementation of, 172
 - efficacy of, 163, 168-170, 170, 172
 - finding therapists for, 171, 172
 - goals of, 166t-167t
 - insurance coverage and, 163
 - limitations of, 172
 - methods, 163-168, 164t, 166t-167t
 - cognitive behavioral therapy for insomnia (CBT-I), 96, 168-171, 169, 170, 172
 - cognitive therapy, 164t, 165, 167t
 - paradoxical intention, 164t, 167t, 168
 - relaxation therapy, 164t, 165-168, 167t
 - sleep hygiene education, 163-165, 164t, 166t
 - sleep restriction therapy, 164t, 165, 167t
 - stimulus control therapy, 164t, 165, 166t
 - in primary care setting, 163, 172
 - target pathways for, 168, 169, 170-171
 - in treatment of anxiety disorders, 143
 - in treatment of OSAS, 157
- Cognitive deficits, associated with insomnia, 73, 74t, 75, 85, 126, 219
- Cognitive therapy, 164t, 165, 167t
- Coma, sleep vs, 19
- Comorbid disorders, 79-85, 91-121, 92t, 143-162. See also *Treatment of insomnia-comorbid disorders*.
 - arthritis, 91

Comorbid disorders (*continued*)

- breathing disorders, 91, 92t, 94, 108-110
- COPD, 108-109
 - treatment of, 156
- OSAS, 109-110
 - treatment of, 156-157
- treatment of, 156-157
- cardiovascular disorders, 79-82, 81, 112-113
 - hyperarousal and, 92t, 113
- diabetes, 80, 82, 82, 91
- gastrointestinal problems, 91, 92t, 94, 113-114
 - GERD, 92t, 113-114
 - treatment of, 158
 - treatment of, 158
- heart disease, 80-82, 81, 91
- heart failure, 80-82, 81
 - treatment of, 158
- hypertension, 80, 81, 91, 94
- management of, 143-162
- medical disorders, 91, 92t
 - cardiovascular disorders, 80-82, 81, 112-113
 - gastrointestinal problems, 91, 92t, 94, 113-114
 - multidirectional relationship to insomnia, 91, 93, 114
 - prevalence of insomnia with, 91, 94
 - mortality and, 83-85, 86
- multidirectional relationship with insomnia, 91, 93, 114, 115
- neurological disorders, 91, 92t, 94, 100-108
 - blindness, 106-107
 - movement disorders, 92t, 103-106
 - treatment of, 156
 - neurodegenerative diseases, 92t, 100-103
 - pain and, 107-108
 - treatment of, 156
- pain, chronic, 94
- prevalence of, 91, 94
- psychiatric disorders, 82-83, 84, 92-100, 92t
 - ADHD, 99
 - anxiety disorders, 92t, 95-96
 - treatment of, 143-146, 145t, 146, 147
 - bipolar disorder, 98
 - depression, 96-97
 - mood disorders, 82-83, 84, 92t, 96-97
 - treatment of, 146-155
 - personality disorders, 92t
 - schizophrenia, 98-99
 - substance abuse, 99-100, 101t
 - treatment of, 143-155, 145t
- sleep-related disorders, 92t
 - circadian rhythm disorders, 92t, 107, 110-112
 - treatment of, 111, 112, 157

Comorbid disorders, sleep-related disorders (*continued*)

- pulmonary disorders, 92t, 108-110
 - treatment of, 156-157
- stomach ulcers, 91
- temporal relationship with insomnia, 91, 93, 123
- treatment of, 143-162. See also *Treatment of insomnia-comorbid disorders*.
- urinary problems, 91, 94
- Comorbid insomnia. See also *Comorbid disorders*.
 - defined, vs secondary, 42
 - in perimenopause and menopause, 54
 - treatment of, 158-159
 - treatment of, 143-162. See also *Treatment of insomnia-comorbid disorders*.
- Complex sleep-related behaviors, 220
- Conditioning, as risk factor for insomnia, 53t
- Congestive heart failure (CHD), 158
 - treatment of, 158
- COPD. See *Chronic obstructive pulmonary disease*.
- Coronary artery disease, 80
- Cortisol, increased levels and insomnia, 61
- Costs associated with insomnia, 77-79. See also *Impairments and burdens associated with insomnia*.
 - health care costs, 77-79
- CPAP, 157
- Criteria for insomnia, 41t, 42-45, 44-45t, 46-48t

- Dalmane (flurazepam), 189t. See also *Flurazepam*.
- Daytime symptoms of insomnia, 39, 73, 124t, 126
 - daytime impairment, 39, 73, 114, 219
- Death of a spouse, as risk factor for insomnia, 53t
- Definition of insomnia, 39-42, 41t
- Delayed sleep-phase disorder, 110-111
 - melatonin for, 178
 - symptoms, 129t
- Delta sleep, 21, 61
- Demographics of insomnia, 45-52
- Dependence on hypnotic medications, 221-225, 222-223
- Depression. See also *Antidepressants*.
 - antidepressants, effects on sleep, 145-155, 150t-151t
 - association with insomnia, 69, 96-97
 - comorbid with insomnia, 82-83, 96-97
 - insomnia as predictor for, 93
 - major depressive disorder (MDD), 82-83, 84
 - insomnia comorbid with, 149
 - mirtazapine for, 227
 - polytherapy with antidepressants and hypnotics, 149, 154-155, 154, 155
 - residual insomnia despite treatment, 153
 - treatment strategies for, 149, 154

- Depression (*continued*)
 morbidity and, 83
 persistence of insomnia in, 148, 152, 153
 recurrence of insomnia in, 93
 as risk factor for insomnia, 53t
 screening for, 132
 suicidal ideation and behaviors, 83, 97
 temporal relationship with insomnia, 96
 treatment of
 antidepressants, 145-155, 150t-151t
 hypnotics, 154-155, 154, 155
 use not FDA approved for depression, 155
 lack of effect or worsening of insomnia, 152, 153
 nonpharmacologic techniques, 149
 triad of insomnia, depression, and anxiety, 97
- Desipramine, 149, 150t
- Diabetes mellitus
 comorbid with insomnia, 80, 82, 82, 91, 94
 incidence of, with insomnia, 80, 82, 82
 prevalence of insomnia with, 94
 severe insomnia and risk of, 82
- Diagnosis of insomnia. See *Evaluation of insomnia*.
Diagnostic and Statistical Manual of Mental Disorders (DSM-5),
 42-43, 44t-45t
- Diazepam, abuse liability of, 222
- Dietary supplements, 175-181, 176t
- Diphenhydramine, 175, 176t
 abuse liability of, 223
- Divorce, as risk factor for insomnia, 53t
- Dopamine agonists, in treatment of RLS, 156
- Dopaminergic (DA) neurons, 30, 31t, 34
- Dopaminergic dysfunction, RLS and, 103
- Doral (quazepam), 189t, 223
- Dorsomedial nucleus of the hypothalamus (DMH), 33-36, 35t
- Doxepin (Silenor), 149, 150t, 154, 202t, 203-205, 226
 abuse potential, lack of association with, 225
 action mechanism, 204
 adverse events, 205
 cautions and contraindications, 205
 dose range, 202t
 effect on sleep variables, 198t, 204
 efficacy, 204
 half-life, 202t
 long-term usage, 216
 pharmacokinetics, 202t
 safety, 205
 tolerability, 205
 use for insomnia, 202t, 203-205, 226
 withdrawal symptoms, 226
- Doxylamine succinate, 175, 176t
- Dreams, 21
 Freud's theories on, 66
- Drowsiness, on awakening, 39
- Drug abuse. See *Substance abuse*.
- DSM-5 (*Diagnostic and Statistical Manual of Mental Disorders*),
 42-43, 44t-45t
- Duration of insomnia, 41, 41t, 43
- Early awakening, 39, 40, 43
- Edluar, 191t. See also *Zolpidem SL*.
- EEG (electroencephalogram), 20, 21, 22t, 24-26, 28
 elevated activity in insomnia, 61
- Elderly patients. See also *Age*.
 cautions for medication use, 219, 220t, 224
 dosage for benzodiazepine receptor agonists (BzRAs), 189t-191t
 falls and, 74-77
 fragmented sleep in, 21, 27, 54, 55
 increased awakenings in, 21
 increased mortality risk, with sleep disturbances, 83-85, 86
 increased risk for insomnia for, 53t, 54, 55
 increased risks associated with, 21
 insomnia in dementia, 54
 prevalence of insomnia in, 54
 sleep disturbances in, 85, 86
 sleep efficiency and, 86
 sleep latency and, 86
- Electroencephalogram (EEG)
 in characterization of sleep stages, 20, 21, 22t, 24-26, 28
 elevated activity in insomnia, 61
 in polysomnographic study, 24-26
- Electromyogram (EMG), 20, 24-26, 28
- Electro-oculogram (EOG), 20, 24-26, 28
- EMG (electromyogram), 20, 24-26, 28
- Enacarbil, 156
- Environmental factors in insomnia, 65-66
 increased sensitivity to, 65
- EOG. See *Electro-oculogram*.
- Epigenetic mechanisms, 66
- Epochs, 22t-23t
- Epworth sleepiness scale, 133
- Escitalopram, 145-146, 146, 147
- Estazolam (Prosom), 189t
 abuse liability, 223
 half-life, 189t
- Eszopiclone (Lunesta), 145-146, 190t
 abuse liability, 222
 combination therapy, 154
 with escitalopram, 145-146, 146, 147
 with fluoxetine, 155

Eszopiclone (Lunesta) (*continued*)
dose range, by gender and impairment, 190t
FDA cautions for, 221
effect on sleep continuity, 197, 199
effect on sleep variables, 145-146, 147, 197, 198t
half-life, 190t, 197
indications and usage, 190t
onset of action, 190t
in treatment of MDD with insomnia, 154, 154
use in menopausal and perimenopausal women, 159

Evaluation of insomnia, 123-142
collateral information, 126-127
daytime impairment and, 39
diagnostic manuals, 42-45
DSM-5, 42-43, 44t-45t
ICD-10, 45, 48t
ISCD-3, 43-45, 46t-47t
dimensions of the insomnia complaint, 123
longitudinal pattern of insomnia, 123
severity of symptoms, 123
temporal relationship with comorbid illnesses, 123
time of onset and duration of symptoms, 123
history, 127-131, 139, 141t
collateral information from family and partners, 126-127
daytime symptoms and behaviors, 124t, 126, 127
factors influencing, 127-131
family history, 131
medical, psychiatric, and surgical history, 130
medications, current and prior use of, 130
organization for history-taking, 124, 139, 141t
perpetuating factors of insomnia, 127-130
precipitants of insomnia, 127
sleep-related patterns and behaviors, 124-125, 124t, 125t
sleep-wake pattern, 124-126, 125t
social and occupational history, 131
of substance abuse, 130-131
key aspects of, 141t
physical examination, 132
primary complaint in, 123, 141t
sleep evaluation tools, 133-137
actigraphy, 133
Epworth sleepiness scale, 133
insomnia severity index, 133, 136t
Mallampati airway classification, 137, 140
scales and inventories, 133-137, 136t
sleep monitoring/logs, 133, 134t-135t
STOP inventory/questionnaire, 137, 138, 139
sleep-wake pattern, 124-126, 125t, 139

Eszopiclone (Lunesta) (*continued*)
symptoms, 39
inquiring about/history of, 123-127, 124t
of specific sleep disorders, 128t-129t
test and consultations, 137-138

Exercise, timing of, 53t, 69t, 125t, 126

Falls, 74-77, 74t
Family history, 131
Fatal familial insomnia, 66
Fatigue, 73, 124t
FDA (Food and Drug Administration)
lowering of recommended dosage for benzodiazepine receptor agonists, 220-221
safety alerts, 17
website, 17
Ferritin levels, in RLS, 137
Fibromyalgia, with comorbid insomnia, 107-108
Flip-flop switch, 33, 34
Flunitrazepam, abuse liability of, 222
Fluoxetine
in combination therapy
with eszopiclone, 155
with hypnotics, 154
effects on sleep variables, 150t
Flurazepam (Dalmane)
abuse liability, 223
half-life, 189t
plasma concentrations, 192
Fluvoxamine, contraindicated with ramelteon, 203
Food and Drug Administration (FDA). See *FDA*.
Fragmented sleep, in elderly patients, 21, 27, 54, 55
Free-running disorder, 112
Freud, Sigmund, 66
Functionality, reduced with insomnia, 74-77, 78, 85, 114, 126

GABA (gamma-aminobutyric acid), 186-187
actions in the CNS, 186-187
in arousal system, 30, 34
benzodiazepine action and, 187-188, 187
GABA-A receptors, 186-188, 187
in generation of sleep, 31t, 187
Gabapentin, 156
Galanin, 31t, 34
Gamma-aminobutyric acid (GABA). See *GABA*.
Gastroesophageal reflux disease (GERD), 113-114
comorbid with insomnia, 92t, 113-114
symptoms of, 128t-129t
treatment of, 158

- Gastrointestinal disorders, 113-114
bidirectional relationship with insomnia, 114
comorbid with insomnia, 91, 92t, 94, 113-114
GERD, 92t, 113-114
incidence of, with insomnia, 91
prevalence of insomnia with, 94
as risk factor for insomnia, 53t
treatment of, 158
- Gastrointestinal reflux, 92t
- Gender
and clearance rates for hypnotic medications, 220-221
risk for insomnia and, 52-54, 53t
- Generalized anxiety disorder (GAD), 95
treatment of, 143-145, 145t
- Genetics factors in insomnia, 65-66
epigenetic mechanisms, 66
family history, 131
genetic predisposition, 68
twin studies, 65-66
- GHB, abuse liability of, 222
- H₁-receptor antagonists, 175, 176t, 184t, 202t, 203-205
doxepin, 202t, 203-205
- Halcion (triazolam), 189t. See also *Triazolam*.
- Haloperidol, 145t
- Hamilton Anxiety Scale, 146, 154, 155
- Health care costs, increased in insomnia, 77-79
- Heart disease
comorbid with insomnia, 80-82, 81, 91, 94
prevalence of insomnia with, 94
as risk factor for insomnia, 53t, 91
- Heart failure, 80-82, 81
congestive heart failure (CHD), 158
treatment of, 158
- Heart rate, elevated, 59, 60t, 63, 63, 79
- Herbal therapies for insomnia, 175-176, 176t, 178-181
- Histamine-1 receptor antagonists, 175, 176t, 184t, 202t, 203-205
doxepin, 202t, 203-205
- Histaminergic (His) neurons, 30, 31t, 34
- History. See also *Evaluation of insomnia, history*.
sleep history, 123-127, 124t
factors influencing, 127-131
- Homeostatic influence, on sleep-wake cycle, 33
behaviors that reduce homeostatic drive, 69t
- Hops, 176t, 180-181
- Hormone replacement therapy, 159
- Hot flashes, 54, 159
- Huntington disease, 102-103
- Hyperarousal, 59-63, 79
cognitive and behavioral constructs and, 66-69, 67, 69t
- Hyperarousal (*continued*)
comorbid conditions and, 79, 113
EEGs in, 61
heart rate and, 59, 60t, 63, 63
metabolic brain activity and, 61-63, 62
neuroendocrine axis and, 61, 62
physiologic measures of, 59, 60t, 63
sleep latency and, 59-60, 61
- Hypertension, 113
comorbid with insomnia, 80, 81, 91, 94
OSA as risk factor for, 102
prevalence of insomnia with, 94
- Hypnotic agents, 175-225. See also *Pharmacologic agents for insomnia; specific agents by generic name*.
abuse liability, 221-224, 222-223
adverse effects, 219-221
benzodiazepine receptor agonists (BzRAs), 184t, 186-199
cautions and contraindications for, 219-221, 220t
alcohol consumption with, 220
complex sleep-related behaviors, 220
clinical considerations for, 211-225
abuse liability, 221-224, 222-223
CNS depression, 186, 219
dependence, abuse, and other precautions, 221-225, 222-223
dosage, 190t-191t, 220-221
dose escalation, 225
guidelines for use, 226t
long-term use, 211-217
intermittent long-term use, 211-212, 213
rebound insomnia, 211
tolerance, 211
PRN and middle-of-the-night use, 217-219
safety, 219-221, 220t
toxicity, 222-223, 224
vulnerable populations, 219-221, 220t
withdrawal effects, 211, 217, 224
in combination with antidepressants, 154-155, 154
effect on sleep time (zolpidem), 145, 146
effects on GERD, 158
falls, lack of attribution to, 74-77
FDA-approved agents for insomnia, 186-225, 189t-191t
use for depression not FDA approved, 155
guidelines for use, 226t
increased mortality risk, potential for, 85
melatonin receptor agonists, 199-203
orexin receptor antagonists, 202t, 205-211
selection of, 183, 219
therapeutic precautions in, 198-199
Hypocretin/orexin neurons, 30, 32-33, 32, 205. See also *Orexins*.
- Hypomania, as risk factor for insomnia, 53t

- Hypothalamic-pituitary-adrenal (HPA) axis
 chronic activation of, 79
 dysregulation in insomnia, 61, 62, 66
 environmental stimuli and, 66
- Hypothalamus, 29, 30, 31t
 dorsomedial nucleus of (DMH), 33-36, 35t
- Hypoventilation, 108
- ICD-10, 45, 48t
- Imipramine, 149, 150t
- Impairments and burdens associated with insomnia, 73-89, 74t.
 See also *Comorbid disorders*.
 cardiovascular and metabolic abnormalities, 79-82, 81, 82
 cognitive deficits, 73, 75, 85
 comorbid disorders, 79-85
 diabetes, 80, 82, 82
 health care costs, 77-79
 mortality and, 83-85, 86
 psychiatric disorders, 82-83, 84
 psychomotor deficits, 75
 quality of life, 77, 78
 reduced functionality, 74-77, 78, 85, 114
- Insomnia. See also *specific topics*.
 characteristics and symptoms of, 39-40
 classification of, 40-45, 41t
 comorbid disorders, 79-85, 91-121, 143-162
 criteria for, 41t, 42-45, 44-45t, 46-48t
 definition of, 39-40
 demographics of, 45-52
 dimensions of, 123
 evaluation of, 123-142
 impairments and burdens associated with, 73-89
 as independent clinical condition, 42, 55-56
 pathophysiology of, 59-71
 polysomnogram depiction of, 40
 predisposing, precipitating, and perpetuating factors, 59, 60, 68
 primary vs secondary, 41-42, 144
 rebound, after abrupt discontinuation of medication, 211
 sleep variables and, 183, 185
 subtypes of. See *Classification*.
 transient vs chronic, 41, 41t
 treatment of. See *Treatment of insomnia*.
- Insomnia severity index, 133, 136t
- Insomnia symptoms. See *Symptoms of insomnia*.
- Intermezzo, 191t. See also *Zolpidem SL*.
- Ipratropium, 156
- Iron supplementation, for RLS, 137, 156
- Irregular schedule, as risk factor for insomnia, 53t
- ISCD-3, 43-45, 46t-47t
- Ischemic stroke. See *Stroke*.
- Jamaican dogwood, 176t
- Jet lag, 111
- Job performance
 cost of lost productivity, 77-79
 impact of insomnia on, 74-77
- Kava kava, 176, 176t, 180
 hepatotoxicity of, 180
- L-tryptophan, 176t, 179-180
- Latency. See *Sleep latency*.
- Lemon balm, 176t, 180-181
- Lifestyle risk factors for insomnia, 53t
- Limbic system, 30
- Lorazepam, abuse liability of, 222
- Lunesta (eszopiclone). See *Eszopiclone*.
- Magnesium, 176t
- Major depressive disorder (MDD). See *Depression, major depressive disorder*.
- Mallampati airway classification, 137, 140
- Mania
 in association with comorbid insomnia, 96, 98
 as risk factor for insomnia, 53t
- MAOIs. See *Monoamine oxidase inhibitors (MAOIs)*.
- Marijuana, interference with sleep by, 100, 101t
- Marital problems, as risk factor for insomnia, 53t
- MDD. See *Depression, major depressive disorder*.
- Medical disorders comorbid with insomnia, 91, 92t
 cardiovascular and metabolic disorders, 79-82, 81-82, 92t, 112-113
 gastrointestinal disorders, 92t, 113-114
 multidirectional relationship to insomnia, 91, 93, 114, 115
 neurological disorders, 92t
 prevalence of insomnia and, 91, 94
- Medical history, 130
- Medical risk factors for insomnia, 53t
- Medications
 history of, 130
 insomnia caused by, 130
 for insomnia. See *Pharmacologic agents for insomnia*.
 secondary effects of, 130, 145-146
- Melatonin, 176-178, 199-201
 elimination half-life, 178
 maintenance of wakefulness through, 201
 receptors (MT₁, MT₂, MT₃), 201
 in regulation of circadian rhythms, 64, 176-178, 199-201
 action mechanism, 178, 199-201
 secretion from pineal gland, 177
 in sleep-promoting system, 31t, 64, 178
 time to action, 178

- Melatonin (*continued*)
 in treatment of circadian rhythm disorders, 112, 157, 178
 in treatment of insomnia, 157
- Melatonin receptor agonists, 16, 184t, 199-203, 202t.
 See also *Ramelteon*.
 action mechanism, 201
 dose range, 202t
 indications for, 201, 202t
 pharmacokinetics, 202t
 ramelteon (Rozerem), 201-203, 202t
 tasimelteon, for treatment of non-24-hour sleep-wake disorder, 107
- Memory, problems with, 73, 126, 127
- Menopause, 54
 depression and, 159
 hormone replacement therapy, 159
 hot flashes and, 54, 159
 insomnia in, 158-159
 treatment of, 158-159
 prevalence of insomnia in, 158
 as risk factor for insomnia, 53t
 as risk factor for obstructive sleep apnea, 159
 sleep apnea and, 54
 sleep disorders and, 54
- Menstrual problems, comorbid with insomnia, 91
- Metabolic rate
 metabolic brain activity, increased, 61-63, 62
 whole-body, 63
- Methamphetamine, interference with sleep by, 101t
- Methaqualone, abuse liability of, 222
- MI. See *Myocardial infarction*.
- Middle-of-the-night (MOTN) awakening, 183, 195-196
- Middle-of-the-night (MOTN) use of insomnia medication, 183, 217-219
- Mirtazapine, 149, 151t, 226-227
- Monoamine oxidase inhibitors (MAOIs)
 contraindication for use of doxepin with, 205
 effects on sleep variables, 149, 150t
 negative effects on sleep, 149
- Mood disorders
 association with insomnia, 82-83, 84, 92t, 96-97
 treatment of, 146-155
- Mortality, sleep disturbance and, 83-85, 86
- MOTN. See *Middle-of-the-night (MOTN)*.
- Motor vehicles
 accidents, 74, 76
 sleep driving, 220
- Movement disorders, 92t, 103-106
 periodic limb movement disorder (PLMD), 104-106
 restless legs syndrome (RLS), 103-104, 104t, 105
 treatment of, 156
- Multiple sleep latency testing (MSLT), 59
- Myocardial infarction (MI), 80, 113
- N1-N3 sleep, 21, 24-26
- Naps, 54, 124t
 avoiding, 166t
 difficulty falling asleep during, 59
 excessive, circadian rhythms and, 126
 frequency of, 126, 127
 inability to nap, 126
 as interfering with sleep, 69t
 level of sleepiness and, 59
- Narcolepsy
 contraindication of suvorexant, 211
 orexin deficiency and, 30, 205
- Nasal obstruction, 132
- National Health and Wellness Survey, 114
- National Institutes of Health: NIH State-of-the-Science Conference
 Statement, 48, 211
- Neck circumference, 132
- Nefazodone, 149, 151t
- Neurobehavioral deficits in insomnia, 75
- Neurodegenerative disorders, 92t, 100-103
 Alzheimer's disease, 100
 Huntington disease, 102-103
 Parkinson's disease, 100-102
 stroke, 102
- Neurological disorders comorbid with insomnia, 91, 92t, 100-108
 blindness, sleep disorders and, 106-107
 movement disorders, 92t, 103-106
 neurodegenerative diseases, 92t, 100-103
 pain, sleep disorders and, 107-108
 prevalence of insomnia with, 94
 treatment of, 156
- Neurological examination, 132
- Neurophysiologic models of insomnia, 59-65
 circadian rhythms, 63-65, 64
 hyperarousal, 59-63
- Neurophysiology of sleep, 30-33, 31t
- Neurotransmitters, 15, 30, 31t, 34
- Nicotinamide, in treatment of insomnia, 176t
- Nicotine
 dependence, 83, 100, 101t
 interference with sleep by, 100, 101t
- Night-shift work, as risk factor for insomnia, 52, 53t, 55
- Nightmares, 97
 treatment strategies, 145
- NIH State-of-the-Science Conference Statement, 48, 211
- Nocturnal panic attacks, 129t
- Nocturnal seizures, 129t

- Non-24-hour sleep-wake disorder, 107, 112
 blindness and, 107, 112
 treatment of, 107
- Non-REM sleep, 20, 21, 22t, 24-26
- Nonbenzodiazepines, 188, 190t-191t
- Nonorganic insomnia, 45, 48t
- Nonpharmacologic therapy for insomnia, 145
- Nonprescription agents for insomnia, 175-182, 176t
 antihistamines, 175, 176t
 herbs, 175-176, 176t, 178-181
 safety issues, 179, 180, 181
 vitamins and supplements, 175-181, 176t
- Noradrenergic neurons, 30, 31t, 34
- Norepinephrine blockade, 148t
- Norepinephrine levels, 61
- Normal sleep, 19-37. See also *Sleep*.
- Normal sleeping patterns
- Nortriptyline, 150t
- Nosology, 40-45
- Obesity, 132
 insomnia and, 80
 as risk factor for insomnia, 53t
- Obesity-hypoventilation syndrome (OHS), 108
- Obstructive sleep apnea syndrome (OSAS), 109-110, 110t.
 See also *Sleep apnea*.
 associated with insomnia, 109-110, 110t
 treatment of, 156-157
- COPD with, 109
- evaluation tools
 Mallampati airway classification, 137, 140
 STOP inventory/questionnaire, 137, 138, 139
- genetic factors in, 131
- insomnia and, 109-110
- morbidity and mortality and, 109
- ramelteon use in, 203
- as risk factor for cardiovascular conditions, 102
- symptoms of, 109, 128t
 treatment of, 156-157
 CPAP for, 157
- Occupational history, 131
- Olanzapine, 145t, 227
- Opioids
 interference with sleep by, 100, 101t
 in treatment of RLS, 156
- Orexin receptor antagonists, 184t, 202t, 205-211. See also *Suvorexant* (*Belsomra*).
 action mechanism, 205
 adverse reactions, 206-211
 approved for treatment of insomnia, 205
- Orexin receptor antagonists (*continued*)
 effects on sleep variables, 206, 207-210
 efficacy and safety, 206, 207-210
 indications and usage, 202t, 205-206
 suvorexant (*Belsomra*), 202t, 205-211
 tolerability, 206-211
- Orexins, 30
 orexin deficiency, narcolepsy and, 30, 205
 orexin neurons, 30, 32-33, 32
 reinforcement of wake-promoting system by, 32-33, 34
 orexin receptors, 205
 wakefulness and, 30, 32-33, 32, 34, 205
- Oropharyngeal abnormalities, 132
- OSAS. See *Obstructive sleep apnea syndrome*.
- Oxazepam, abuse liability of, 223
- Pain, 107-108
 association with insomnia, 107-108
 association with neurologic disorders, 107-108
 chronic
 fibromyalgia and, 107-108
 prevalence of insomnia with, 94
 as risk factor for insomnia, 53t
 sensitivity to, 107
- Panic attacks, nocturnal, 129t
- Paradoxical intention, 164t, 167t, 168
- Paraldehyde, in early therapy for insomnia, 184
- Parkinson's disease, 100-102
 in association with comorbid insomnia, 100-102
 as risk factor for insomnia, 53t
- Paroxetine
 in combination therapy, with hypnotics, 154
 effects on sleep variables, 150t
- Passionflower, 176, 176t
- Pathophysiology of insomnia, 59-71
 genetic and environmental models, 65-66
 neurophysiologic models, 59-65
 hyperarousal, 59-63
 predisposing, precipitating, and perpetuating factors in, 59, 60, 68
 psychological models, 66-69, 67
- Patrinia root, 176t
- Pentobarbital, 186, 222
- Perfectionism, association with insomnia, 69
- Perimenopause, insomnia in, 54, 158-159
 treatment of, 158-159
- Periodic leg movements (PLMs), 28, 227
- Periodic limb movement disorder (PLMD), 104-106
 associated with insomnia, 104-106
 diagnosis of, 106
 symptoms of, 128t
 vs RLS, 103-104

Perpetuating factors of insomnia, 127-130
Persistence of insomnia, despite treatment of anxiety/mood disorders, 93, 148, 152, 153
Personality disorders, 92t
Pharmacologic agents for insomnia, 183-234, 184t. See also *specific agents*.
anticonvulsants/antiepileptics, 184t, 227
antidepressants, sedating, 184t, 225-227
antipsychotics, 184t, 227
barbiturates, 186
benzodiazepine receptor agonists (BzRAs), 184t, 186-199
 benzodiazepines, 188, 189t
 nonbenzodiazepines, 188, 190t-191t
categories of agents, 184t
chloral hydrate, 184-186
clinical considerations for, 211-225
 abuse liability, 221-224, 222-223
 CNS depression, 186, 219
 dependence, abuse, and other precautions, 221-225, 222-223
 dosage, 190t-191t, 220-221
 dose escalation, 225
 guidelines for hypnotic use, 226t
 long-term use, 211-217
 intermittent long-term use, 211-212, 213
 rebound insomnia, 211, 212
 tolerance, 211
 withdrawal effects, 211, 217, 224
 PRN and middle-of-the-night use, 217-219
 safety, 219-221, 220t
 toxicity, 222-223, 224
 vulnerable populations, 219-221, 220t
combining with behavioral therapies, 168-170, 170
effect on sleep variables, 183, 185, 197-198, 198t
H₁-receptor antagonists, 184t, 202t, 203-205
history of, 184-186
ideal agent, characteristics of, 183-184
indications for, 144, 189t-191t
long-term use, 211-217
melatonin receptor agonists (ramelteon), 184t, 199-203, 202t
mid-nocturnal administration, 183, 217-219
nonprescription agents, 175-182, 176t. See also *Nonprescription agents for insomnia*.
orexin receptor agonists, 184t, 202t, 205-211
 suvorexant, 202t, 205-211
overview, 16, 183-184, 184t
pharmacokinetic properties, 183, 189t-191t
 half-life/elimination rate, 183, 189t-191t
 ideal medication, characteristics of, 183-184
 onset of action, 183, 189t-191t

Pharmacologic agents for insomnia (*continued*)
 prescribed agents, 184t
 FDA-approved for insomnia, 184t, 186-225, 189t-191t
 not FDA-approved for insomnia, 184t, 225-227
 PRN and middle-of-the-night use, 217-219
 in treatment algorithm, 144
Phenelzine, 150t
Phenobarbital, 186
Physical examination, 132
Pineal gland, 176, 177
Plasma concentrations, of benzodiazepine receptor agonists, 188, 192, 193
PLMD. See *Periodic limb movement disorder*.
Polysomnography, 24-26, 25-28
 of awake patient, 24
 characterization of sleep stages via, 24-26
 components of, 20, 24
 of insomnia, 40, 40
 of N1-N3 sleep, 24-26
 patient undergoing, 28
 of REM sleep, 26
Polytherapy
 antidepressants plus hypnotics, for MDD with insomnia, 149, 154-155, 154, 155
 trazodone as additive therapy, 152-154
Posttraumatic stress disorder (PTSD), 95
 symptoms of, 129t
 treatment of, 145
Pramipexole, in treatment of RLS, 156
Precipitants of insomnia, 127
Predisposing, precipitating, and perpetuating factors, 59, 60, 68, 127-130
Pregnancy, 54
 medication cautions and contraindications in
 benzodiazepine receptor agonists (BzRAs), 198-199
 doxepin, 205
 hypnotic agents, 219-220
 ramelteon, 203
 suvorexant, 211
Prevalence of insomnia, 15, 45-52, 49-52
 in American adults, 45-49, 50
 comorbid with medical problems, 91, 94
 in elderly individuals, 54
 NIH State-of-the-Science Conference Statement, 48
 in primary care, 48-52, 51, 52
 symptoms and diagnosis, 45, 49
Primary care, 15, 217
 discussions about insomnia in, 49-52, 51, 52
 implementing cognitive and behavioral therapy in, 163, 172
 prevalence of insomnia in, 48-52, 51, 52

Primary insomnia
classification of, 42
definition of, 39-42
in treatment algorithm, 144
vs secondary insomnia, 41-42

PRN (as-needed) use of insomnia medication, 217-219

Prosom (estazolam), 189t. See also *Estazolam*.

Prostatic hypertrophy, symptoms, 129t

Proton pump inhibitors, 158

Protriptyline, 149

Psychiatric disorders comorbid with insomnia, 82-83, 84, 92-100, 92t.
See also *specific disorders*.
ADHD, 99
anxiety disorders, 82, 92-93, 92t, 95-96
bi-directional relationship with insomnia, 83, 91, 93, 96-97, 115
bipolar disorder, 98
depression, 93, 96-97
drugs used in treatment of, effects on sleep
antidepressants, 145-155, 150t-151t
antipsychotics, 145, 145t, 227
incidence of, with insomnia, 83, 84
insomnia as predictive factor in, 96-97
mood disorders, 82-83, 84, 92t, 96-97
treatment of, 143-155, 145t
personality disorders, 92t
schizophrenia, 98-99
substance abuse, 99-100, 101t
time-relationship with insomnia, 83, 91, 93, 96-97
treatment of, 143-155
persistence of insomnia despite treatment, 148, 152, 153
treatment strategies, 149, 152
triad of insomnia, depression, and anxiety, 97

Psychiatric history, 130

Psychiatric medications that may precipitate insomnia, 130

Psychiatric risk factors for insomnia, 53t

Psychological models of insomnia, 66-69, 67
cognitive and behavioral constructs, 66-69, 67
psychoanalytic models, 66

Psychomotor deficits, 75

Psychophysiological insomnia, symptoms of, 128t

PTSD. See *Posttraumatic stress disorder*.

Pulmonary disorders comorbid with insomnia, 92t, 108-110.
See also *Sleep-related breathing disorders*.

Quality of life, 74t, 77, 78, 114

Quality of sleep. See *Sleep quality*.

Quazepam (Doral), 189t, 223

Quetiapine, 145t, 227

R & K sleep stage scoring system, 20-21, 22t-23t

Ramelteon (Rozerem), 201-203, 202t
abuse potential, lack of association with, 225
adverse events, 203
cautions and contraindications, 203
dose range, 202t
effect on sleep variables, 198t, 201, 203
efficacy, 201
half-life, 202t
indications for, 201, 202t
indicated use for insomnia, 201, 202t
use in OSAS and COPD, 203
lack of abuse liability, 223
long-term usage, 212-216, 216
onset of action, 202t
pharmacokinetics, 202t

Rapid eye movement sleep. See *REM*.

Rechtschaffen and Kales (R & K) sleep scoring, 20-21, 22t-23t

Relaxation therapy, 164t, 165-168, 167t

REM sleep, 20, 22t
dreams and, 21
effect of antidepressants on, 150t-151t
effect of barbiturate on, 186
polysomnography of, 26
in sleep scoring systems, 21, 22t
vs non-REM, 20, 21, 22t

Respiratory disease, as risk factor for insomnia, 53t

Rest, sense of, decrease in, 39, 40, 55

Restless legs syndrome (RLS), 103-104, 104t, 105
in association with insomnia, 103-104
diagnostic criteria, 104t
dopamine and, 103-106
hereditary component of, 131
iron deficiency and, 137
iron supplementation and, 137, 156
as risk factor for insomnia, 53t
serum ferritin level and, 137
symptoms of, 103, 105, 128t
treatment of, 156
vs PLMD, 103-104

Restoril (temazepam), 189t. See also *Temazepam*.

Risk factors for insomnia, 52-55, 53t
elderly individuals, 53t, 54, 55
gender, 52-55, 53t
other risk factors, 55

Risperidone, 145t

RLS. See *Restless legs syndrome (RLS)*.

Ropinirole, in treatment of RLS, 156

Rotigotine, in treatment of RLS, 156

Rozerem (ramelteon). See *Ramelteon*.

Safety. See also *specific agents and therapies*.
 FDA safety alerts, 17

Schizophrenia, in association with comorbid insomnia, 98-99

SCN. See *Suprachiasmatic nucleus*.

Scullcap, 176t, 180-181

Seasonal affective disorder, 96

Secobarbital, 186

Secondary insomnia, 42, 46t. See also *Comorbid disorders*.
 in treatment algorithm, 144

Sedatives, 131

Seizures, nocturnal, 129t

Selective norepinephrine reuptake inhibitors (SNRIs), 149, 150t

Selective serotonin reuptake inhibitors (SSRIs)
 in combination therapy, with hypnotics, 154
 effects on sleep variables, 149, 150t

Serotonin (5-HT) receptor modulators, 151t

Serotonin reuptake inhibitors (SSRIs)
 in combination therapy, with hypnotics, 154
 effects on sleep variables, 149, 150t

Serotonin syndrome, 152

Serotonergic (5-HT) neurons, 30, 31t, 34

Sertraline
 in combination therapy, with hypnotics, 154
 effects on sleep variables, 150t

Shift work
 inquiring about during evaluation, 126
 as risk factor for insomnia, 52, 53t, 55

Shift-work sleep disorder, 55, 111-112
 treatment of, 157, 178

Short-term insomnia, 47t

Silenor (doxepin). See *Doxepin*.

Sleep. See also *Bedtime*.
 behavioral characteristics of, 19-20
 brain activity during, 19-21, 24-26, 36
 brainstem mechanisms underlying, 28-33, 29
 disruption of, 19
 flip-flop switch, 33, 34
 functions of, 19, 36
 importance of, 36
 neurophysiology of, 30-33, 31t
 normal sleep, 19-37
 REM vs non-REM, 20, 21, 22t, 24-26
 restorative function of, 19, 36
 transitions between wakefulness and, 33, 34, 36
 vs coma, 19
 and wakefulness, mechanisms underlying, 28-33, 29

Sleep apnea
 in menopause, 54
 as risk factor for cardiometabolic disease, 79
 as risk factor for insomnia, 53t

Sleep architecture, 20, 20

Sleep deprivation, effects of, 19

Sleep driving, 220

Sleep efficiency
 effect of age on, 55
 in elderly adults, 86

Sleep environment, 53t. See also *Bedtime*.

Sleep evaluation tools, 133-137

Sleep fragmentation
 age and elderly patients, 21, 27, 54, 55
 characteristics of, 21

Sleep history
 in evaluation of insomnia, 123-127, 124t
 factors influencing, 127-131

Sleep hygiene, 127, 163-165
 for circadian rhythm disorder, 157
 education in, 163-165, 164t, 166t

Sleep latency, 124t, 183, 185
 abnormal level for, 59
 defined, 39, 183
 effect of antipsychotics on, 145t
 effect of benzodiazepine receptor agonists on, 188, 194, 198t
 effect of eszopiclone and escitalopram on, 147
 in elderly adults, 86
 in evaluation/history, 124t
 hyperarousal and, 59-60, 61
 mortality and, 86
 multiple sleep latency testing (MSLT), 59
 prolonged, polysomnographic depiction of, 40

Sleep logs, 133, 134t-135t

Sleep monitoring, 133, 134t-135t

Sleep needs, variation in, 21

Sleep parameters. See *Sleep variables*.

Sleep-promoting system, 15, 30-33, 31t
 flip-flop switch for, 33, 34
 inhibition of wake-promoting neurons, 31t, 32
 transitions between wakefulness and, 33, 34, 36
 VLPO neurons in, 31t, 32-33, 34

Sleep quality, 49, 65
 disturbance of, 43, 49
 comorbid disorders and, 74, 76, 80, 83, 98, 99, 108, 114
 motor vehicle accidents and, 74, 76

Sleep reactivity, 65

Sleep-related behaviors, possible with hypnotic agents, 220

Sleep-related breathing disorders, 91, 92t, 94, 108-110
 chronic obstructive pulmonary disease (COPD), 91, 108-109
 obstructive sleep apnea syndrome (OSAS), 109-110, 110t
 treatment of, 156-157

Sleep-related disorders comorbid with insomnia, 92t
 circadian rhythm disorders, 92t, 110-112

- Sleep-related disorders comorbid with insomnia (*continued*)
- pulmonary disorders, 92t, 108-111
 - chronic obstructive pulmonary disease (COPD), 91, 108-109
 - obstructive sleep apnea syndrome (OSAS), 109-110, 110t
 - treatment of, 156-157
 - Sleep restriction therapy, 164t, 165, 167t
 - Sleep scales and inventories, 133-137, 136t
 - Sleep stages
 - age, effect on, 21, 27
 - characteristics of, 20-21, 22t-23t
 - scoring systems, 20-21, 22t-23t
 - Sleep-state misperception, 40
 - Sleep variables, 183, 185
 - effect of antidepressants on, 149, 150t-151t
 - effect of benzodiazepine receptor agonists, 197-198, 198t
 - effect of eszopiclone and escitalopram on, 147
 - sleep latency, 39, 183, 185
 - total sleep time (TST), 183, 185
 - wake after sleep onset (WASO), 183, 185, 198t
 - Sleep-wake pattern in insomnia, 124-126, 139
 - Sleep walking, 127
 - Slow-wave sleep, 22t
 - Smoking, as risk factor for insomnia, 53t
 - Snoring, 127
 - SNRIs (selective norepinephrine reuptake inhibitors), 149, 150t
 - Social history, 131
 - Social risk factors for insomnia, 53t
 - Social status, as risk factor for insomnia, 53t
 - Sonata (zaleplon). See *Zaleplon*.
 - SSRIs (selective serotonin reuptake inhibitors), 149, 150t, 154
 - St. John's wort, 176t
 - Stages of sleep
 - age, effect on, 21, 27
 - polysomnography of, 24-26
 - scoring systems, 20-21, 22t-23t
 - Stage 1 sleep, 21, 22t, 24-25
 - increase with age, 21
 - Stage 2 sleep, 22t, 25
 - Stage 3 sleep, 21, 26
 - Stimulants, interference with sleep by, 100, 101t, 130-131
 - Stimulus control therapy, 164t, 165, 166t
 - Stomach ulcers, 91
 - STOP inventory/questionnaire, 137, 138, 139
 - STOP-BANG score, 137, 139
 - Stress
 - chronic activation of, 79
 - as initiating factor in insomnia, 68
 - as risk factor for insomnia, 53t
 - sensitivity to, 65, 66, 69
 - Stroke
 - OSAS and, 109
 - relationship of insomnia to, 102
 - Submarine duty, 112
 - Substance abuse, 130-131
 - and abuse of hypnotic medications, 224
 - in association with insomnia, 99-100, 101t, 130
 - history of, 130-131
 - as risk factor for insomnia, 53t
 - risk of, insomnia and, 83, 84
 - Subtypes of insomnia. See *Classification*.
 - Suicidal ideation/behavior, sleep disturbance and, 83, 97
 - Sulfonyl, in early therapy for insomnia, 184
 - Suprachiasmatic nucleus (SCN)
 - melatonin receptors in, 201
 - in regulation of circadian rhythms, 33, 35t, 199-201
 - Surgical history, 130
 - Suvorexant (Belsomra), 202t, 205-211. See also *Orexin receptor antagonists; Orexins*.
 - abuse potential, aspects of, 225
 - use with alcohol or other abused drugs, 225
 - action mechanism, 205
 - adverse reactions, 206-211, 218t
 - cautions and contraindications, 211
 - dose range, 202t
 - effects on sleep variables, 198t, 206, 207-210
 - similar effects regardless of gender and ethnicity, 206
 - sleep latency, 206, 207, 209
 - sleep maintenance, 206, 208, 210
 - WASO, 206, 208
 - efficacy and safety, 206-211, 207-210, 216-217
 - half-life, 202t
 - indications and usage, 202t, 205-206
 - approved for treatment of insomnia, 205
 - lack of next-day symptoms/impairment, 221
 - long-term usage, 216-217, 218t
 - withdrawal symptoms, 217
 - peak concentrations, 206
 - pharmacokinetics, 202t, 206
 - as schedule IV, controlled medication, 211
 - tolerability, 206-211
- SWSD. See *Shift-work sleep disorder*.
- Symptoms of insomnia, 39-40, 55
 - awakenings during night, 39
 - daytime impairment, 39, 73, 114
 - daytime symptoms, 124t, 126
 - difficulty falling asleep (sleep latency), 39, 183, 185
 - DSM-5 and, 43
 - duration of, 123
 - evaluation/history of, 123-127, 124t

Symptoms of insomnia (*continued*)

- fatigue, 73
- frequency of, 50
- severity of, 123, 136t
- for specific sleep disorders, 128t-129t
- time of onset of, 123, 124
- waking up feeling drowsy, 39
- waking up too early, 39, 43

Tasimelteon, 107

TCA, 149

Temazepam (Restoril), 188, 189t, 222

Tension, as risk factor for insomnia, 53t

Testosterone

- decrease, with ramelteon, 203
- deficiency, as risk factor for insomnia, 53t

Thalamus, 31t, 32

Thiothixane, 145t

Thoughts and behaviors associated with insomnia, 66-69, 67

- beliefs about sleep, 68, 125
- maladaptive behavioral practices, 68-69, 69t

Thyroid disorder, as risk factor for insomnia, 53t

Thyroid function tests, 137

Tiagabine, use for insomnia, 227

Time zone change syndrome (jet lag), 111

Tolerance

- to barbiturates, 186
- to hypnotics, 211

Total sleep time (TST), 183, 185

- effect of benzodiazepine receptor agonists on, 197
- effect of eszopiclone and escitalopram on, 147

Toxicity

- with hypnotic agents, 222-223, 224
- of kava kava, 180

Toxins, exposure to, 131

Transient insomnia, 41, 41t

Transitions between wakefulness and sleep, 33, 34, 36

Tranlycypromine, 150t

Trazodone, 226

- abuse liability, 223
- caution for use with antidepressants, 152
- in combination with antidepressants, 152-154
- effects on sleep variables, 150t
- half-life, 226
- sedating effects of, 149, 152
- use for insomnia, 226

Treatment of insomnia. See also *specific treatment categories and pharmacologic agents.*

- algorithm for, 144
- behavioral strategies, 163-174

Treatment of insomnia (*continued*)

and comorbid conditions, 143-162. See also *Treatment of insomnia-comorbid disorders.*

- as independent clinical condition, 42, 55-56
- management of comorbid disorders and, 143-162
- nonprescription agents, 175-182, 176t
- pharmacologic agents, 183-234
- treatment strategies, 143, 144

Treatment of insomnia-comorbid disorders, 143-162.

See also *Comorbid disorders.*

- antidepressants, 145-155, 150t-151t
 - antipsychotics, 145t
 - anxiety/mood disorders, 143-155, 145t
 - breathing disorders, 156-157
 - COPD, 156
 - OSAS, 156-157
 - circadian rhythm disorder, 111, 112, 157
 - gastrointestinal disorders, 158
 - heart failure, 158
 - movement disorders, 156
 - neurologic conditions, 156
 - perimenopausal women, insomnia in, 158-159
 - psychiatric disorders, 143-155
 - anxiety disorders, 143-146, 145t, 146
 - mood disorders, 146-155
 - sleep-related breathing disorders, 156-157
 - treatment effect on insomnia management, 143
 - treatment prior to treating insomnia, 144
 - treatment strategies, 149, 152
- Triad of insomnia, depression, and anxiety, 97
- Triazolam (Halcion), 189t, 211, 222
- Tricyclic antidepressants, 149
- doxepin, approved use in insomnia, 202t, 203-205, 226
 - effects on sleep variables, 149, 150t
 - nonsedating, 149
 - overdose, potential fatality from, 227
 - sedating, 149, 226
- Trimipramine, 149, 150t
- Tryptophans, 176t, 179-180
- Twin studies, 65-66

Unemployment, as risk factor for insomnia, 53t

Urethan, in early therapy for insomnia, 184

Urinary problems, comorbid with insomnia, 91, 94

Valerian, 176, 176t, 178-179

dosage, recommended, 179

Venlafaxine, effects on sleep variables, 151t

Ventrolateral preoptic nucleus (VLPO) neurons, 31t, 32-33, 34

Vitamins and supplements, 175-181, 176t

VLPO neurons, 31t, 32-33, 34

Wake after sleep onset (WASO), 183, 185, 198t

effect of antipsychotics on, 145t

effect of benzodiazepine receptor agonists on, 188, 197, 198t

effect of eszopiclone and escitalopram on, 147, 197

Wake-promoting system, 15, 30, 31t

factors modulating, 33-36, 35t

flip-flop switch for, 33, 34

inhibition of wake-promoting neurons, 31t, 32

Wakefulness, 28-33, 29

arousal neurophysiology, 29, 30, 31t

mechanisms underlying, 28-33, 29

orexin and, 30, 32-33, 32, 34

transitions between sleep and, 33, 34, 36

in wake-promoting system, 30, 31t

Waking up feeling drowsy, 39

WASO. See *Wake after sleep onset (WASO)*.

Wild lettuce, 176t

Women

dosage lowering for, 190t-191t, 220-221

menopause and, 53t, 54, 158-159

risk for insomnia and, 52-54, 53t

Work performance

cost of lost productivity, 77-79

impact of insomnia on, 74-77

Working conditions, as risk factor for insomnia, 53t

Worry, 126

at bedtime, 125t

as risk factor for insomnia, 53t, 69

Zaleplon (Sonata), 190t

abuse liability, 222

benzodiazepine-receptor binding by, 187-188

dose range, by gender and impairment, 190t

effect on sleep latency, 194, 198t

effect on sleep variables, 198t

effect on total sleep time, 197

flexibility regarding timing of administration, 219

half-life, 190t, 219

indications and usage, 190t, 219

long-term usage, 212

plasma concentrations, 193

as selective benzodiazepine receptor agonist (sBzRA), 187-188

Ziprasidone, 145t

Zolpidem (Ambien), 187-197, 190t

abuse liability, 223

adverse events, 197, 198

benzodiazepine-receptor binding by, 187-188

Zolpidem (Ambien) (*continued*)

in combination with antidepressants, for MDD with insomnia, 154, 154

dose range, by gender and impairment, 190t, 220-221

lowering of doses by FDA, 220-221

effect on sleep latency, 197, 198t

effect on sleep time, 145, 198t

effect on sleep variables, 198t

effect on WASO, 198t

fibromyalgia pain and, 108

half-life, 190t

indications and usage, 188, 190t-191t

long-term use

intermittent long-term use, 211-212, 213

withdrawal effects, 211

newer formulations of, 188-197

onset of action, 190t-191t

pharmacokinetics, 194

plasma concentrations, 193

as selective benzodiazepine receptor agonist (sBzRA), 187-188

sublingual formulations, 188-197, 191t

adverse events, 197

dosages, 191t, 220-221

efficacy and safety, 195-197, 196, 197, 198t

indications and usage, 191t, 195, 219

MOTN awakenings and, 195-196, 196, 197, 219

onset of action, 191t, 195

tolerability, 197

zolpidem oral spray (Zolpimist, sublingual spray), 191t, 195, 198t

zolpidem SL (Edluar, sublingual tablet), 191t, 198t

zolpidem SL (Intermezzo, sublingual tablet), 191t, 198t

tolerability, 197

in treatment of MDD with insomnia, 154, 154

in treatment of primary insomnia, 108, 188, 190t

vs zolpidem ER, 194, 198, 200

Zolpidem ER (Ambien CR), 188, 190t

in combination with escitalopram, 145

dose range, by gender and impairment, 190t, 220

effect on sleep continuity, 197-198, 198t

effect on sleep variables, 197, 198t

half-life, 190t

indications and usage, 190t

long-term use, 212, 214-215

pharmacokinetics, 188, 194

plasma concentrations, 188

use for GAD, 145

vs zolpidem, 194, 198, 200

Zolpidem oral spray (Zolpimist), 191t, 198t

dose range, by gender and impairment, 191t, 220-221

effect on sleep variables, 198t

Zolpidem oral spray (Zolpimist) (*continued*)
indications and usage, 191t, 195

Zolpidem SL (sublingual tablets)
adverse events, 197
dose range, by gender and impairment, 191t, 220-221

Edluar (sublingual tablet), 191t
effect on sleep variables, 198t
efficacy and safety, 195-197, 196, 197, 198t
indications and usage, 191t, 195, 219
for MOTN awakenings, 219

Intermezzo (sublingual tablet), 191t
tolerability, 197

Zolpimist. See *Zolpidem oral spray*.

Zopiclone, abuse liability of, 222